NASDAQ
3.09USD
-0.08 (-2.52%)
We have scored 7 news catalysts on Sana Biotechnology, Inc. (SANA) over the past 12 months. The biggest single-day move next to one of them came Oct 15, 2025, when SANA closed +33.0%: “Sana Biotech Stock — The Next '100-Bagger'?”. Coverage across the window leans positive (average ticker sentiment +0.29). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
859.9M
P/E
—
EPS
—
Beta
2.13
52W range
2.61-6.55
Day range
3.00–3.19
Open
3.10
Prev close
3.17
Volume
4.6M
Avg volume
3.4M
Dividend
0.00
IPO
2021-02-04
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Sana Biotechnology, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SANA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
